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Introduction: The progressive dementia that is characteristic of Alzheimer’s disease is associated with the
accumulation of amyloid-beta (Aβ) peptides in extracellular plaques and within neurons. Aβ peptides are targeted
to cholesterol-rich membrane micro-domains called lipid rafts. Observations that many raft proteins undertake
recycling pathways that avoid the lysosomes suggest that the accumulation of Aβ in neurons may be related to
Aβ targeting lipid rafts. Here we tested the hypothesis that the degradation of Aβ by neurons could be increased
by drugs affecting raft formation.
Methods: Primary neurons were incubated with soluble Aβ preparations. The amounts of Aβ42 in neurons or
specific cellular compartments were measured by enzyme-linked immunosorbent assay. The effects of drugs on the
degradation of Aβ42 were studied.
Results: Aβ42 was targeted to detergent-resistant, low-density membranes (lipid rafts), trafficked via a pathway that
avoided the lysosomes, and was slowly degraded by neurons (half-life was greater than 5 days). The metabolism of
Aβ42 was sensitive to pharmacological manipulation. In neurons treated with the cholesterol synthesis inhibitor
squalestatin, less Aβ42 was found within rafts, greater amounts of Aβ42 were found in lysosomes, and the half-life of
Aβ42 was reduced to less than 24 hours. Treatment with phospholipase A2 inhibitors or platelet-activating factor (PAF)
antagonists had the same effects on Aβ42 metabolism in neurons as squalestatin. PAF receptors were concentrated in
the endoplasmic reticulum (ER) along with enzymes that constitute the cholesterol ester cycle. The addition of
PAF to ER membranes triggered activation of cholesterol ester hydrolases and the release of cholesterol from
stores of cholesterol esters. An inhibitor of cholesterol ester hydrolases (diethylumbelliferyl phosphate) also
increased the degradation of Aβ42 in neurons.
Conclusions: We conclude that the targeting of Aβ42 to rafts in normal cells is a factor that affects its degradation.
Critically, pharmacological manipulation of neurons can significantly increase Aβ42 degradation. These results are
consistent with the hypothesis that the Aβ-induced production of PAF controls a cholesterol-sensitive pathway that
affects the cellular localization and hence the fate of Aβ42 in neurons.* Correspondence: cbate@rvc.ac.uk
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The amyloid hypothesis of Alzheimer’s disease (AD)
pathogenesis maintains that the primary event is the pro-
duction of specific C-terminal amyloid-beta (Aβ) peptides
following the abnormal proteolytic cleavage of the amyloid
precursor protein [1]. Aβ oligomers demonstrate disease-
specific accumulation in human brain and cerebrospinal
fluid [2]. The accumulation of Aβ peptides leads to the
subsequent disruption of neuronal processes, abnormal
phosphorylation of tau [3], and synapse degeneration [4].
Currently, soluble Aβ42 oligomers are regarded as potent
neurotoxins [5,6].
Neurodegeneration is preceded by the intraneuronal ac-
cumulation of Aβ [7,8]. The chronic nature of AD sug-
gests that it is a slow accumulation of Aβ that triggers
neurodegeneration and hence the clinical symptoms.
Whereas the factors that affect the production of the Aβ
have been studied extensively, the capacity of neurons to
degrade Aβ once it has been formed has received less
attention. Thus, the accumulation of Aβ within neurons
may result from a slow rate of degradation. Aβ peptides
can be degraded by proteases, including neprilysin [9],
insulysin [10], cathepsin B [11], and acyl peptide hydrolase
[12]. The observation that Aβ was degraded more quickly
in microglial cells than in neurons (unpublished data)
raised the question of whether the rate of degradation of
Aβ within neurons could be increased.
Studies that use synthetic Aβ preparations may be
compromised by their propensity to self-aggregate into a
wide variety of oligomer sizes and conformations. The
polymorphic nature of Aβ aggregates suggests that there
exist disease-relevant conformations of Aβ but that
other conformations are less toxic [13,14]. It is difficult
to control the size and conformation of synthetic Aβ42
oligomers in aqueous medium and consequently it is not
clear which of the Aβ conformations are responsible for
specific biological properties. To overcome this problem,
conditioned media from 7PA2 cells (7PA2-CM) which
contain naturally secreted Aβ oligomers [15] were used
in this study. The Aβ oligomers secreted by these cells
are sodium dodecyl sulphate (SDS)-stable, as are the Aβ
oligomers found within the cerebrospinal fluid of pa-
tients with AD [16-18]. Although 7PA2-CM includes
other amyloid precursor protein (APP) metabolites, in-
cluding Aβ40 and p3, we decided to specifically measure
Aβ42 peptides because of the close association of this
isoform with disease.
Aβ42 peptides are found in detergent-resistant, cholesterol-
dense membrane micro-domains which are commonly
referred to as rafts [19-21]. Since many raft-associated
proteins traffic through cells via recycling pathways that
avoid the lysosomes [22,23], we hypothesized that the
targeting of Aβ42 to rafts caused it to avoid the lysosomes
and degradation. Thus, the targeting of Aβ42 to rafts maycontribute to their gradual accumulation within neu-
rons and subsequently their toxic effects. In this study,
non-toxic concentrations of Aβ42 were taken up by
cultured neurons and targeted to detergent-resistant
membranes (DRMs) (lipid rafts). As a consequence, it
was slowly degraded and had a half-life of greater than
5 days. As the formation and function of lipid rafts is
dependent upon the amount of cholesterol within cell
membranes [24-26], the effects of the cholesterol synthesis
inhibitor squalestatin [27] on the cellular targeting of Aβ42
were studied. Here, we show that, in neurons treated with
squalestatin, significantly less Aβ42 was targeted to rafts
and more was found within lysosomes. Consequently, in
squalestatin-treated neurons, the half-life of Aβ42 was
reduced to less than 24 hours. Such results indicate that
the pharmacological manipulation of neurons can alter
the clearance of Aβ42.
Methods
Primary neuronal cultures
Cortical neurons were prepared from the brains of mouse
embryos (day 15.5). Neurons were plated at 106 cells per
well in six-well plates in Ham’s F12 containing 5% fetal calf
serum for 2 hours. Cultures were shaken (600 rpm for
5 minutes), and non-adherent cells were removed by two
washes in phosphate-buffered saline (PBS). Neurons were
subsequently grown in neurobasal medium containing B27
components supplemented with 5 nM brain-derived nerve
growth factor for 10 days. Immunohistochemistry showed
that the cells were greater than 95% neurofilament-
positive. Less than 3% stained for glial fibrillary acidic pro-
tein (astrocytes) or for F4/80 (microglial cells). Neurons
were pre-treated with test compounds for 3 hours before
the addition of Aβ preparations, and the amount of Aβ42
in treated neurons was measured at specific time points
thereafter. All experiments were performed in accordance
with European regulations (European community Council
Directive, 1986, 56/609/EEC) and approved by the Royal
Veterinary College ethics committee.
Cell extracts
Neurons were washed twice with PBS and homogenized
in a buffer containing 10 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium
deoxycholate, 0.2% SDS, and mixed protease inhibitors
(4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride
(AEBSF), Aprotinin, Leupeptin, Bestatin, Pepstatin A, and
E-46) (Sigma-Aldrich, St. Louis, MO, USA) at 106 cells/mL.
Nuclei and large fragments were removed by centrifugation
(300 g for 5 minutes).
Isolation of detergent-resistant membranes
These membranes were isolated by their insolubility in
non-ionic detergents as described [28]. Briefly, cells were
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X-100, 10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 10 mM
EDTA, and mixed protease inhibitors at 106 cells/mL,
and nuclei and large fragments were removed by centri-
fugation (300 g for 5 minutes at 4°C). The post-nuclear
supernatant was incubated on ice (4°C) for 1 hour and
centrifuged (16,000 g for 30 minutes at 4°C). The super-
natant was reserved as the detergent-soluble membrane;
the insoluble pellet was homogenized in an extraction
buffer containing 10 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium
deoxycholate, 0.2% SDS, and mixed protease inhibitors
at 106 cells/mL and was centrifuged (10 minutes at
16,000 g); and the soluble material was reserved as the
DRM fraction.
Sucrose density isolation
Neurons were harvested with a Teflon scraper and col-
lected at 800 g for 5 minutes. Cell pellets were homoge-
nized in a buffer containing 250 mM sucrose, 10 mM
Tris-HCl (pH 7.4), 1 mM EGTA, mixed protease inhibi-
tors, and 1 mM dithiothreitol at 106 cells/mL. Particulate
membrane fragments and nuclei were removed by cen-
trifugation (1,000 g for 5 minutes). Membranes were
washed by centrifugation at 16,000 g for 10 minutes at 4°C
and suspended in an ice-cold buffer containing 1% Triton
X-100, 10 mM Tris-HCl pH 7.2, 150 mM NaCl, 10 mM
EDTA. Sucrose solutions of 5%, 10%, 15%, 20%, 25%, 30%,
and 40% were prepared and layered over each other.
Solubilized membranes were added on top and centrifuged
at 50,000 g for 18 hours at 4°C. Serial 1-mL aliquots were
collected from the bottom of gradients.
Isolation of lysosomes
Lysosomes were isolated by using a lysosome enrich-
ment kit designed for cultured cells in accordance with
the instructions of the manufacturer (Pierce, Rockford,
IL, USA). Briefly, treated cells were collected and ho-
mogenized in ice-cold lysosome enrichment reagents
containing protease inhibitors (as above). The cell ex-
tract was overlaid on a discontinuous density gradient
prepared from OptiPrep™ media and centrifuged at
145,000 g for 2 hours at 4°C. Serial 1-mL aliquots were
collected from the bottom of gradients. The lysosome
fraction was collected, washed three times in PBS
(18,000 g for 30 minutes at 4°C), and solubilized in an
extraction buffer containing 10 mM Tris-HCl pH 7.4,
100 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5%
sodium deoxycholate, 0.2% SDS, and protease inhibitors
(as above). Samples were mixed with an equal volume of
Laemmli buffer, boiled, and subjected to electrophoresis
on a 15% polyacrylamide gel. Proteins were transferred
onto a Hybond-P polyvinylidiene fluoride (PVDF) mem-
brane by semi-dry blotting. Membranes were blocked byusing 10% milk powder in PBS containing 0.2% Tween 20.
Blots were probed with anti-lysosome-associated mem-
brane protein 1 (LAMP-1) (Pharmingen, San Diego, CA,
USA) followed by peroxidase-labelled anti-rabbit antibodies
and visualized by using enhanced chemiluminescence.
Isolation of endoplasmic reticulum
Endoplasmic reticulum (ER) fractions were isolated from
treated cells by using an ER preparation kit (Sigma-Aldrich)
in accordance with the instructions of the manufacturer.
Homogenized cell extracts were separated on a discontinu-
ous density gradient (OptiPrep™). Serial 1-mL aliquots were
collected from the bottom of gradients. Fractions were
diluted 1:20 in carbonate buffer and distributed into Nunc
Maxisorp immunoplates (Nunc, Roskilde, Denmark) over-
night. Plates were blocked with 5% milk powder and probed
with monoclonal antibody (mAb) reactive to the ER marker
Grp 78 (Stressgen Biotechnology, Victoria, Canada), poly-
clonal anti-PAF receptor (Cayman Chemical Company, Ann
Arbor, MI, USA), anti-cholesterol ester hydrolase (CEH)
(LifeSpan BioSciences, Seattle, WA, USA), or anti-acyl-
coenzyme A:cholesterol acyltransferase (ACAT) (Abcam,
Cambridge, UK), followed by biotinylated anti-rabbit IgG
(Sigma-Aldrich), extravidin-alkaline phosphatase (Sigma-
Aldrich), and the addition of the substrate p-nitrophenyl
phosphate (p-NPP), 1 ng/mL, diluted in diethanolamine
buffer. Optical density was read in a spectrophotometer at
405 nm.
Cholesterol and protein content
Protein concentrations were measured by using a micro-
BCA protein assay kit (Pierce). The amount of choles-
terol was measured by using the Amplex Red cholesterol
assay kit (Invitrogen, Carlsbad, CA, USA). Cholesterol
was oxidized by cholesterol oxidase to yield hydrogen
peroxide and ketones. The hydrogen peroxide reacts
with 10-acetyl-3, 7-dihydroxyphenoxazine (Amplex Red)
to produce highly fluorescent resorufin, which is mea-
sured by excitation at 550 nm and emission detection at
590 nm. Samples were incubated in the presence or ab-
sence of cholesterol esterase to determine the amounts
of esterified cholesterol.
Drugs
Arachidonyl trifluoromethyl ketone (AACOCF3), acetyl
salicylic acid, diethylumbelliferyl phosphate (DEUP),
ginkgolide B, ibuprofen, platelet-activating factor (PAF), 1-
O-Hexadecyl-2-acetyl-sn-glycerol-3-phospho-(N,N,N-tri-
methyl)-hexanolamine (Hexa-PAF), methyl arachidonyl
fluorophosphonate (MAFP), acetyl salicylic acid, ibu-
profen, simvastatin, and squalene were all obtained from
Sigma-Aldrich. Squalestatin was a gift from GlaxoSmithK-
line (Uxbridge, Middlesex, UK). Stock solutions were
dissolved in ethanol or di-methyl sulphoxide and diluted
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controls consisted of equivalent dilutions of ethanol or di-
methyl sulphoxide in culture medium.Preparation of Aβ-containing medium
Conditioned media (CM) from Chinese hamster ovary
(CHO) cells stably transfected with a cDNA encoding
APP751 (referred to as 7PA2 cells) was cultured in
Dulbecco’s modified Eagle’s medium with 10% fetal calf
serum as described [15]. CM from these cells contains
stable Aβ (7PA2-CM). 7PA2-CM was centrifuged at
100,000 g for 4 hours at 4°C to remove cell debris and then
passed through a 50-kDa filter (Sartorius, Goettingen,
Germany) before use. To demonstrate Aβ species, con-
centrated 7PA2-CM was mixed 1:1 with (0.5% NP-40,
5 mM CHAPS, 50 mM Tris-HCl, pH 7.4, and mixed pro-
tease inhibitors) and separated by polyacrylamide gel elec-
trophoresis (PAGE) under non-denaturing conditions.
Proteins were transferred onto a Hybond-P PVDF mem-
brane (Amersham Biotech, now part of GE Healthcare,
Little Chalfont, Buckinghamshire, UK) by semi-dry blot-
ting. Membranes were blocked by using 10% milk powder
and incubated with mAb 6E10 reactive with amino
acids 1 to 16 of human Aβ (Signet, part of Covance,
Princeton, NJ, USA). Bound mAbs were detected with
biotinylated anti-mouse IgG, extravidin-peroxidase, and
enhanced chemiluminescence.Size exclusion chromatography
7PA2-CM or brain extracts were concentrated by desalt-
ing columns (3-kDa filter; Sartorius) and injected into a
Superdex 75 PC column (separates peptides ranging
from 3 to 70 kDa) (GE Healthcare) and eluted at a rate
of 0.2 mL/minute. Fractions were collected and tested
by Aβ enzyme-linked immunosorbent assay (ELISA) (see
below).Sample preparation
To detach Aβ42 from cellular binding proteins that could
occlude specific epitopes, cell extracts (200 μL) were
mixed with 500 μL of 70% formic acid and sonicated. A
50-μL aliquot was added to 450 μL of 1 M Tris-HCl
with protease inhibitors (as above) and sonicated before
addition to ELISA.Synthetic Aβ
A peptide corresponding to amino acids 1 to 42 of Aβ
(Aβ1-42) was obtained from Bachem (Bubendorf, Switzerland)
and dissolved in hexafluoroisopropanol, lyophilized,
and stored at −80°C. On the day of use, it was dissolved in
dimethylsulphoxide at 1 mM, diluted in culture medium,
and sonicated prior to addition to cells.Aβ42 enzyme-linked immunosorbent assay
Nunc Maxisorp immunoplates were coated with mAb 4G8
(epitope 17-24) (Covance) in carbonate buffer overnight.
Plates were blocked with 5% milk powder in PBS-tween,
and samples were applied. The detection antibody was an
Aβ42 selective rabbit mAb BA3-9 (Covance) followed by
biotinylated anti-rabbit IgG (Sigma-Aldrich). Total Aβ was
visualized by addition of the substrate (pNPP) 1 ng/mL,
diluted in diethanolamine buffer, and optical density was
read in a spectrophotometer at 405 nm.
Statistical methods
Differences between treatment groups were assessed by
using Student t tests.
Results
Squalestatin increased the degradation of Aβ42
The amount and distribution of cholesterol are recognized
as factors that affect the progression of AD [29,30]. As
squalestatin reduced the cholesterol content of cultured
neurons [31], the fate of Aβ42 in squalestatin-treated neu-
rons was examined. Treatment with 200 nM squalestatin
for 24 hours reduced the cholesterol content of neurons
from 519 ng cholesterol/106 cells ± 48 to 369 ng ± 66, n = 6,
P <0.05, without affecting neuronal viability as measured
by thiazolyl blue tetrazolium (MTT). Both treated and
untreated neurons were subsequently incubated with
7PA2-CM containing 10 nM Aβ42, a mixture of mono-
mers, dimers, trimers, and tetramers as shown in
Figure 1A. An analysis of concentrated 7PA2-CM by
size exclusion chromatography also showed that it
contained three main peaks corresponding to mono-
mers, dimers, and trimers (Figure 1B). The concentra-
tions of Aβ42 used did not affect neuronal survival
during the 5-day incubation period. In control neu-
rons, Aβ42 had a half-life of greater than 5 days,
whereas in squalestatin-treated neurons, the half-life of
Aβ42 was reduced to less than 24 hours (Figure 1C).
Aβ42 was not detected in cell supernatants, suggesting
that the Aβ42 had been digested rather than secreted
from neurons. Experiments performed using synthetic
Aβ1-42 showed that it behaved like the cell-derived
Aβ42; it had a half-life of greater than 5 days in untreated
neurons and a much shorter half-life in squalestatin-
treated neurons (Figure 1D).
Similar results were obtained in neurons that had been
treated with 1 μM simvastatin, a clinically approved hy-
droxymethyl glutaryl coenzyme A reductase inhibitor
that also reduced cellular cholesterol levels. As choles-
terol depletion has been demonstrated to affect the ex-
pression of some receptors, including the cellular prion
protein [32] and acetylcholine receptors [33], the possi-
bility that it reduced the binding of Aβ42 to neurons was
explored. There were no significant differences in the
Figure 1 Squalestatin increased the degradation of Aβ42. (A)
Immunoblot showing amyloid-beta (Aβ) monomers (M), dimers (D),
and trimers (T) in conditioned media from 7PA2 cells (7PA2-CM) (1)
and in Aβ-depleted 7PA2-CM (2). (B) Aβ monomers, dimers, and
trimers eluted from a Superdex 75 PC column (separates proteins
ranging from 3 to 70 kDa) loaded with concentrated 7PA2-CM.
Values are mean Aβ42 of duplicates. (C) Neurons were pre-treated
with control medium (●) or 200 nM squalestatin (○), pulsed with
7PA2-CM containing 10 nM Aβ42, and incubated for 1 to 5 days as
shown. Values are mean Aβ42 remaining in neurons ± standard
deviation (SD) from triplicate experiments performed four times
(n = 12). (D) Neurons were pre-treated with control medium (●) or
200 nM squalestatin (○), pulsed with 100 nM synthetic Aβ42, and
incubated for 1 to 5 days as shown. Values are mean Aβ42 in
neurons ± SD from triplicate experiments performed four times
(n = 12). (E) Neurons were pre-treated with control medium (■) or
200 nM squalestatin (□) and pulsed with 7PA2-CM containing Aβ42
as shown for 2 hours. Values are mean neuronal Aβ42 ± SD from
triplicate experiments performed three times (n = 9). (F) Neurons,
incubated with 7PA2-CM containing 10 nM Aβ42 for 2 days, were
treated with control medium (■) or 200 nM squalestatin (□) for
24 hours. Values are the mean Aβ42 remaining in neurons ± SD from
triplicate experiments performed three times (n = 9). *Concentrations
of Aβ42 significantly less (P <0.05) than controls.
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squalestatin-treated neurons, indicating that cholesterol
depletion did not affect the binding of Aβ42 to neurons
(Figure 1E). In further studies, neurons were pulsed with
10 nM Aβ42; after 2 days, 200 nM squalestatin was
added, and cell extracts were collected 1 day later. The
amount of Aβ42 in squalestatin-treated neurons was sig-
nificantly less than in mock-treated neurons (Figure 1F).
Squalestatin altered the distribution of Aβ42 in neurons
Next, we looked at the distribution of Aβ42 within neu-
rons. In control neurons incubated with 10 nM Aβ42 for
2 hours, most Aβ42 was found within DRMs, observa-
tions that are consistent with reports that membrane-
bound Aβ was recruited into lipid rafts [19-21,34,35]. In
squalestatin-treated neurons, significantly less Aβ42 was
found within DRMs (Figure 2A). Since many of the pro-
teins that are targeted to lipid rafts traffic via a recycling
pathway that avoids the lysosomes [23,36], an organelle
fractionation technique was used to examine the target-
ing of Aβ42 to lysosomes. Organelles from neurons were
separated on a density gradient, and lysosomes were
identified by using immunoblots for lysosome-associated
antigen 1 (LAMP-1), a marker of late endosomes/lysosomes.
LAMP-1 was enriched within fractions 4 to 6, which were
subsequently pooled to represent the lysosomes (Figure 2B).
Firstly, we showed that treatment with 200 nM squalestatin
did not affect the amount of the LAMP-1 found in neurons
(Figure 2C). Next, treated neurons were incubated with 10
nM Aβ42 for 2 hours, and the amount of Aβ42 in lysosomes
was measured. The amounts of Aβ42 in lysosomes from
squalestatin-treated neurons were significantly higher than
the amounts of Aβ42 in lysosomes from control neurons
(Figure 2D).
Squalene reversed the effect of squalestatin on the
cellular distribution of Aβ42
One explanation of these results is that the squalestatin-
induced reduction in cholesterol disrupts the formation of
lipid rafts that direct Aβ42 into a pathway that avoids the
lysosomes. This hypothesis was tested by incubating
neurons with combinations of squalestatin and squalene.
The addition of 5 μM squalene alone did not increase
cholesterol concentrations above those of control cells
(527 ng cholesterol/106 cells ± 28 to 519 ng ± 48, n = 6, P
= 0.74), but the addition of 5 μM squalene reversed the ef-
fects of 200 nM squalestatin on cellular cholesterol con-
centrations (496 ng cholesterol/106 cells ± 45 to 369 ng ±
66, n = 6, P <0.05). The addition of 5 μM squalene also
reversed the effects of 200 nM squalestatin on the traffick-
ing of Aβ42; the amount of Aβ42 in DRMs was significantly
lower and the amount in lysosomes significantly higher in
neurons treated with squalestatin when compared with
neurons treated with a combination of squalestatin and
Figure 2 Squalestatin alters the cellular distribution of Aβ42. (A)
Concentrations of Aβ42 in detergent-resistant membranes (DRMs) (rafts)
or detergent-soluble membranes (DSMs) 2 hours after the addition of
conditioned media from 7PA2 cells (7PA2-CM) containing 10 nM Aβ42 to
neurons pre-treated with control medium (■) or 200 nM squalestatin (□).
Values are mean ± standard deviation (SD) from triplicate experiments
performed three times (n = 9). (B) Cell extracts from neurons were
separated on sucrose density gradients and analyzed by immunoblot for
lysosome-associated membrane protein 1 (LAMP-1), a marker of
lysosomes. (C) Immunoblot showing the amount of LAMP-1 in extracts
from neurons treated with control medium or 200 nM squalestatin. (D)
The amount of Aβ42 in lysosomes derived from neurons treated with
control medium (□) or 200 nM squalestatin (□) and incubated with
7PA2-CM containing 10 nM Aβ42 for 2 hours. Values are mean ± SD from
triplicate experiments performed three times (n = 9). *Concentrations of
Aβ42 significantly higher (P <0.05) than controls.
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on the degradation of Aβ42 by neurons was reversed by
the addition of squalene. When neurons incubated with
10 nM Aβ42 for 2 days were subsequently treated with
combinations of squalestatin and squalene for 24 hours,Table 1 Squalene reversed the effects of squalestatin
upon Aβ42 trafficking
Concentration of Aβ42, nM
Cell extracts DRMs Lysosomes
Control 8.7 ± 0.7 8.4 ± 0.6 0.4 ± 0.2
Squalestatin 8.7 ± 1 2.4 ± 0.6a 2.8 ± 0.5b
Squalene 8.5 ± 0.85 8 ± 0.4 0.5 ± 0.2
Squalestatin + squalene 8.3 ± 0.6 7.9 ± 0.9 0.3 ± 0.1
Neurons were pre-treated with 200 nM squalestatin, 5 μM squalene, or a mixture
of squalestatin and squalene and then incubated with conditioned media from
7PA2 cells (7PA2-CM) containing 10 nM Aβ42 for 2 hours. The concentrations of
Aβ42 in whole cell extracts, detergent-resistant membranes (DRMs) (lipid rafts),
and lysosomes were measured by enzyme-linked immunosorbent assay.
Values are the mean concentration of Aβ42 ± standard deviation from
triplicate experiments performed three times (n = 9). aAmounts of Aβ42
significantly lower than in control cells. bAmounts of Aβ42 significantly
higher than in control cells.the amounts of Aβ42 in neurons treated with 200 nM
squalestatin and 5 μM squalene were significantly higher
than in neurons treated with 200 nM squalestatin alone
(8.9 nM Aβ42 ± 0.8 compared with 2.4 nM Aβ42 ± 0.6,
n = 9, P <0.01).
Phospholipase A2 and platelet-activating factor affect the
degradation of Aβ42
As Aβ activates cytoplasmic phospholipase A2 (cPLA2)
[37-40], an enzyme that is implicated in tubule formation
and intracellular trafficking [41-43], specifically within the
trans-Golgi network [44], the effects of cPLA2 inhibitors
on Aβ42 distribution were studied. Neurons were pulsed
with 7PA2-CM containing 10 nM Aβ42 for 2 hours and
were washed, and cell extracts were collected at time
points thereafter. Pre-treatment of neurons with cPLA2
inhibitors (1 μM AACOCF3 or MAFP) significantly
reduced the half-life of Aβ42 in neurons (Figure 3A). As
the activation of cPLA2 results in the production of pros-
taglandins and PAF, specific inhibitors/antagonists of these
mediators were also tested. The half-life of Aβ42 was re-
duced in neurons pre-treated with PAF receptor antago-
nists (1 μM ginkgolide B or 1 μM Hexa-PAF) (Figure 3B)
but not in neurons pre-treated with cyclo-oxygenase in-
hibitors (1 μM aspirin or 2 μM ibuprofen) that reduce the
production of prostaglandins. In neurons pre-treated with
ginkgolide B or Hexa-PAF, the half-life of Aβ42 was re-
duced to less than 24 hours. The addition of 1 μM Hexa-
PAF to neurons that had been incubated with 10 nM Aβ42
for 2 days resulted in the increased degradation of
Aβ42 (Figure 3C). Aβ42 was not detected in the super-
natants collected from either control or treated neu-
rons, indicating that it was not secreted. Such results
suggest that PAF, produced in response to Aβ42-induced
activation of cPLA2, regulates the trafficking and hence
the degradation of Aβ42 in neurons. In support of this hy-
pothesis, we found that the addition of 1 μM PAF reversed
the effects of the cPLA2 inhibitor (AACOCF3) upon the
degradation of Aβ42 in neurons (Figure 3D). Experiments
performed using synthetic Aβ1-42 showed that it had a
half-life of approximately 24 hours in neurons pre-
treated with Hexa-PAF (Figure 3E).
Hexa-PAF altered the distribution of Aβ42 in neurons
As the effects of Hexa-PAF on the neuronal degradation
of Aβ42 were similar to those of squalestatin, its effects
upon cellular distribution of Aβ42 were studied. After
the addition of 10 nM Aβ42 for 2 hours, we found no
significant differences in the amounts of cell-associated
Aβ42 between control and Hexa-PAF-treated neurons
(9.1 nM Aβ42 ± 0.7 compared with 8.7 ± 1, n = 9, P = 0.32).
However, pre-treatment of neurons with 1 μM Hexa-PAF
or 1 μM ginkgolide B significantly reduced the amount of
Aβ42 found within DRMs (Figure 4A). Since the detergent
Figure 3 Platelet-activating factor (PAF) receptor antagonists
increased the degradation of Aβ42. (A) Amounts of Aβ42 in
neurons pre-treated with control medium (●), 1 μM AACOCF3 (○), or
1 μM MAFP (□), pulsed with conditioned media from 7PA2 cells
(7PA2-CM) containing 10 nM Aβ42, and incubated for 1 to 5 days.
Values are mean ± standard deviation (SD) from triplicate experiments
performed four times (n = 12). (B) Amounts of Aβ42 in neurons
pre-treated with control medium (●), 1 μM Hexa-PAF (○), or 1 μM
ginkgolide B (□), pulsed with 7PA2-CM containing 10 nM Aβ42, and
incubated for 1 to 5 days. Values are mean ± SD from triplicate
experiments performed four times (n = 12). (C) Neurons were
incubated with 7PA2-CM containing 10 nM Aβ42. After 2 days,
1 μM Hexa-PAF (○) or control medium (●) was added and the
amounts of Aβ42 were measured thereafter. Values are mean
Aβ42 ± SD from triplicate experiments performed four times
(n = 12). (D) Neurons were pre-treated with control medium (●),
1 μM PAF (□), 1 μM AACOCF3 (○), or a combination of 1 μM
AACOCF3 and 1 μM PAF (■) and incubated with 7PA2-CM
containing 10 nM Aβ42 for 1 to 5 days. Values are mean Aβ42 ± SD
from triplicate experiments performed three times (n = 9). (E) The
amount of Aβ42 in neurons pre-treated with control medium (●)
or 1 μM Hexa-PAF (○), pulsed with 100 nM synthetic Aβ42, and
incubated for 1 to 5 days. Values are mean ± SD, from triplicate
experiments performed four times (n = 12). AACOCF3, arachidonyl
trifluoromethyl ketone; Hexa-PAF, 1-O-hexadecyl-2-acetyl-sn-glycerol-
3-phospho-(N,N,N-trimethyl)-hexanolamine; MAFP, methyl
arachidonyl fluorophosphonate.
Figure 4 Platelet-activating factor (PAF) receptor antagonists
altered the distribution of Aβ42 in neurons. (A) The amount of
Aβ42 in detergent-soluble membrane (DSM) (□) or detergent-
resistant membrane (DRM) (■) extracts from neurons pre-treated
with control medium, 1 μM ginkgolide B, or 1 μM Hexa-PAF and
pulsed with conditioned media from 7PA2 cells (7PA2-CM) containing
10 nM Aβ42 for 2 hours. Values are mean ± standard deviation
(SD) from triplicate experiments performed four times (n = 12).
*Concentration of Aβ42 significantly higher (P <0.05) than in
control neurons. (B) Neurons treated with control medium (●) or
1 μM Hexa-PAF (□) and pulsed with 7PA2-CM containing 10 nM
Aβ42 for 2 hours. Cell extracts were separated on sucrose density
gradients. Values are mean Aβ42 ± SD from triplicate experiments
(n = 3). (C) Immunoblot showing the amounts of lysosome-
associated membrane protein 1 (LAMP-1) in neurons treated with
control medium or 1 μM Hexa-PAF. (D) Neurons were pre-treated
with control medium (□), 1 μM Hexa-PAF, 1 μM ginkgolide B, or
1 μM PAF and pulsed with 7PA2-CM containing 10 nM Aβ42
for 2 hours when lysosomes were isolated. Values are mean Aβ42 ±
SD from triplicate experiments performed four times (n = 12).
*Concentration of Aβ42 significantly higher (P <0.05) than in
control neurons. Hexa-PAF, 1-O-hexadecyl-2-acetyl-sn-glycerol-3-
phospho-(N,N,N-trimethyl)-hexanolamine.
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rons were incubated for 2 hours with 10 nM Aβ42 and
membranes were separated on sucrose density gradients.
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density membrane fractions. In neurons pre-treated with
1 μM Hexa-PAF, less of the Aβ42 was found within low-
density fractions (Figure 4B). Although treatment with
1 μM Hexa-PAF did not affect the amount of the LAMP-
1 found in neurons (Figure 4C), the amounts of Aβ42 in
lysosomes from neurons pre-treated with Hexa-PAF or
ginkgolide B were significantly higher than the amounts of
Aβ42 in lysosomes from control neurons (Figure 4D).Figure 5 Platelet-activating factor (PAF) increased cholesterol
in the endoplasmic reticulum (ER) of neurons. (A) Neuronal
extracts were separated by density gradient centrifugation and
analyzed for PAF receptor (□) and the ER marker Grp 78 (■). (B) The
amounts of cholesterol in ER fractions incubated with control
medium (□), 1 μM squalestatin, or 2 μM PAF or pre-treated with
squalestatin and incubated with PAF (■) for 1 hour. Values are mean ±
standard deviation (SD) from triplicate experiments performed
three times (n = 9). *Concentration of cholesterol significantly
higher (P <0.05) than in controls. (C) The amounts of cholesterol
esters in ER fractions incubated with control medium (□), 1 μM
squalestatin, or 2 μM PAF or pre-treated with squalestatin and
incubated with PAF (■). Values are mean ± SD from triplicate
experiments performed three times (n = 9). *Concentration of
cholesterol esters significantly lower (P <0.05) than in controls.The effects of Hexa-PAF are not reversed by squalene
The similar effects of squalestatin and Hexa-PAF upon
Aβ42 trafficking suggested that Hexa-PAF may affect
cholesterol synthesis. However, treatment with either
1 μM PAF or 1 μM Hexa-PAF did not significantly affect
the amounts of cholesterol in neurons and the addition
of 5 μM squalene did not reverse the effects of Hexa-
PAF upon the targeting of Aβ42 to DRMs or lysosomes
(Table 2) nor alter the half-life of Aβ42 in Hexa-PAF-
treated neurons, indicating that Hexa-PAF did not affect
cholesterol synthesis. Next, we explored the hypothesis
that PAF increased cholesterol in specific cellular com-
partments. We sought to identify such compartments by
separating organelles upon density gradients. PAF recep-
tors were found in high concentrations in fractions 6 to
8 (Figure 5A), fractions that also contained Grp78, a
marker of the ER. These fractions were subsequently
pooled and incubated with or without PAF. The addition
of 2 μM PAF caused a significant increase in cholesterol
(Figure 5B). The PAF-induced increase in cholesterol in
these fractions was not blocked by the inclusion of 200
nM squalestatin, indicating that PAF was not stimulating
cholesterol synthesis. Conversely, the addition of PAF
significantly reduced the amounts of cholesterol esters
in ER fractions (Figure 5C).Table 2 Squalene does not reverse the effects of
Hexa-PAF upon Aβ42 trafficking
Concentration of Aβ42, nM
Cell extracts DRMs Lysosomes
Control 8.7 ± 0.7 8.4 ± 0.6 0.4 ± 0.2
Hexa-PAF 8.5 ± 1.2 2.5 ± 0.9a 3 ± 0.6b
Squalene 8.5 ± 0.9 8 ± 0.4 0.5 ± 0.2
Hexa-PAF + squalene 8.8 ± 0.6 2.8 ± 0.8a 3 ± 0.4b
Neurons were pre-treated with 1 μM Hexa-PAF, 5 μM squalene, or a mixture of
Hexa-PAF and squalene and then incubated with conditioned media from
7PA2 cells (7PA2-CM) containing 10 nM Aβ42 for 2 hours. The amounts of Aβ42
in whole cell extracts, detergent-resistant membranes (DRMs) (lipid rafts), and
lysosomes were measured by enzyme-linked immunosorbent assay. Values
are the mean concentration of Aβ42 ± standard deviation from triplicate
experiments performed three times (n = 9). aAmounts of Aβ42 significantly
lower than in control cells. bAmounts of Aβ42 significantly higher than in
control cells. Hexa-PAF, 1-O-hexadecyl-2-acetyl-sn-glycerol-3-phospho-
(N,N,N-trimethyl)-hexanolamine.Platelet-activating factor stimulates the release of
cholesterol from stores of cholesterol esters
To determine the source of the PAF-induced increase in
cholesterol, other methods of cholesterol regulation were
explored. The amounts of cholesterol within cells is
tightly controlled via a mixture of synthesis, uptake,
and efflux and by esterification of cholesterol [45]. The
cholesterol ester cycle involves the esterification of chol-
esterol by ACAT and the storage of cholesterol esters as
cytoplasmic droplets [46]. Conversely, the hydrolysis of
cholesterol esters results in the release of cholesterol
from these stores. Thus, the cholesterol ester cycle helps
maintain a constant level of cholesterol in cell mem-
branes [46,47]. Our findings that that both ACAT and
CEH were concentrated in the ER fractions along with
PAF receptors (Figure 6A) suggested that PAF-induced
activation of CEH released cholesterol. To explore the
role of CEH in the trafficking of Aβ42, an inhibitor of
CEH (DEUP) was used [48]. Treatment with 20 μM
DEUP did not significantly affect total neuronal
Figure 6 Platelet-activating factor (PAF) causes the release of
cholesterol in the endoplasmic reticulum (ER). (A) Neuronal
extracts were separated by density gradient centrifugation and
analyzed for cholesterol ester hydrolase (CEH) (□) and anti-acyl-
coenzyme A:cholesterol acyltransferase (ACAT) (■). (B) The amount
of cholesterol in ER fractions pre-treated with control medium (□),
20 μM diethylumbelliferyl phosphate (DEUP), or 2 μM PAF or
pre-treated with DEUP and incubated with PAF (■). Values are mean
± standard deviation (SD) from triplicate experiments performed
three times (n = 9). *Significantly less (P <0.05) cholesterol than ER
fractions incubated with PAF. (C) The amount of cholesterol esters
in ER fractions incubated with control medium (□), 20 μM DEUP, or
2 μM PAF or pre-treated with DEUP and incubated with PAF (■).
Values are mean ± SD from triplicate experiments performed three
times (n = 9). *Significantly more (P <0.05) cholesterol esters than ER
fractions incubated with PAF. (D) Neurons treated with control
medium (●) or 20 μM DEUP (○) were pulsed with conditioned
media from 7PA2 cells (7PA2-CM) containing 10 nM Aβ42 and
incubated for 1 to 5 days as shown. Values are mean Aβ42 ± SD from
triplicate experiments performed four times (n = 12). (E) The amount
of Aβ42 in neurons pre-treated with control medium (●) or 20 μM
DEUP (○), pulsed with 100 nM synthetic Aβ42, and incubated for 1 to
5 days. Values are mean Aβ42 ± SD from triplicate experiments
performed four times (n = 12).
Table 3 Squalene does not reverse the effects of DEUP
upon Aβ42 trafficking
Concentration of Aβ42, nM
Cell extracts DRMs Lysosomes
Control 8.7 ± 0.7 8.4 ± 0.6 0.4 ± 0.2
DEUP 8.6 ± 0.9 2.2 ± 0.7a 2.8 ± 0.3b
Squalene 8.5 ± 0.9 8 ± 0.4 0.5 ± 0.2
DEUP + squalene 8.9 ± 0.8 2 ± 0.6a 2.7 ± 0.3b
Neurons were pre-treated with 20 μM diethylumbelliferyl phosphate (DEUP),
5 μM squalene, or a mixture of DEUP and squalene and then incubated with
conditioned media from 7PA2 cells (7PA2-CM) containing 10 nM Aβ42 for
2 hours. The amounts of Aβ42 in whole cell extracts, detergent-resistant
membranes (DRMs) (lipid rafts), and lysosomes were measured by enzyme-linked
immunosorbent assay. Values are the mean concentration of Aβ42 ± standard
deviation from triplicate experiments performed three times (n = 9). aAmounts of
Aβ42 significantly less than in control cells.
bAmounts of Aβ42 significantly higher
than in control cells.
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519 ng ± 48, n = 6, P = 0.26). However, pre-treatment of
ER fractions with 20 μM DEUP blocked the PAF-inducedincrease in cholesterol (Figure 6B) and the PAF-induced
reduction in cholesterol esters (Figure 6C). Pre-treatment
of neurons with 20 μM DEUP did not alter the amount of
Aβ42 that bound to neurons, but reduced the amounts of
Aβ42 in DRMs and increased the amounts of Aβ42 in lyso-
somes (Table 3). As a consequence, the half-life of Aβ42 in
DEUP-treated cells was reduced to approximately 24 hours
(Figure 6D). Pre-treatment of neurons with 20 μM DEUP
also reduced the half-life of synthetic Aβ1-42 to approxi-
mately 24 hours (Figure 6E). Notably, these effects of
DEUP were not reversed by the inclusion of 5 μM squa-
lene, indicating that they were not mediated by inhibition
of cholesterol synthesis. Collectively these results suggest
that CEH regulates the hydrolysis of cholesterol esters in
the ER which is involved in the trafficking of Aβ42.
Discussion
This study showed that Aβ42 taken up by cultured neu-
rons was found predominantly within lipid rafts, traffics
via a pathway that avoids the lysosomes and conse-
quently was cleared slowly. We hypothesize that the
slow clearance of Aβ42 from neurons is a significant fac-
tor in the accumulation of Aβ42 within the brain and
leads to synapse damage and dementia in AD. Critically
we show that these properties are dependent upon Aβ42-
induced activation of PLA2, the production of PAF, and
the activation of CEH, the blockade of which alters the
distribution of Aβ42 in neurons and greatly increased its
degradation.
This study used nanomolar concentrations of Aβ
which did not affect the viability of neurons and which
were similar to those found in the cerebrospinal fluid
[49,50] or in soluble brain extracts from patients with
AD [51-53]. In control neurons, most of the Aβ was
found within rafts, an observation consistent with re-
ports that Aβ in the brain is found within cholesterol-
dense membrane rafts [19-21]. Reports that Aβ affects
Figure 7 Platelet-activating factor (PAF)-mediated hydrolysis of
cholesterol esters stabilizes amyloid-beta (Aβ)-containing lipid rafts.
Schematic demonstrating the putative mechanism regulating the
formation of Aβ-containing rafts. In this theory, Aβ42 activates cPLA2, result-
ing in the production of PAF. PAF activates cholesterol ester hydrolase
(CEH) and the release of cholesterol from stores of cholesterol esters,
which stabilizes Aβ42 in rafts. Inhibition of cPLA2 (arachidonyl trifluoro-
methyl ketone, or AACOCF3), antagonism of the PAF receptors (Hexa-PAF),
or inhibition of CEH (diethylumbelliferyl phosphate, is DEUP) reduces the
cholesterol concentrations in the endoplasmic reticulum (ER). cPLA2,
cPLA2 is cytoplasmic phospholipase A2; Hexa-PAF, 1-O-hexadecyl-2-acetyl-
sn-glycerol-3-phospho-(N,N,N-trimethyl)-hexanolamine.
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Aβ modifies the biochemistry of cell membranes and
thus creates the rafts that are responsible for its traffick-
ing. The targeting of Aβ42 to rafts may have important
biological consequences as many of the proteins that are
targeted to rafts avoid the classic endocytic trafficking
pathway that ends in the lysosomes [22,57]. Our obser-
vations were compatible with Aβ42 trafficking via a re-
cycling pathway in neurons as little Aβ42 was found
within lysosomes and consequently Aβ42 had a long
half-life (over 5 days) in these neuronal cultures.
Here, we show that the trafficking of Aβ42 within neurons
could be affected by inhibiting cholesterol synthesis. Chol-
esterol has multiple effects upon cells, including altering
membrane fluidity, protein trafficking, endocytosis, and
exocytosis [58]. More specifically, cholesterol is important
for the formation and function of membrane rafts, and in
cholesterol-depleted neurons, most of the Aβ42 was ex-
cluded from such rafts. Consequently, more Aβ42 was
found within lysosomes and the half-life of Aβ42 was
reduced from over 5 days in untreated neurons to less than
24 hours in squalestatin-treated neurons. Squalestatin was
used because it inhibits squalene synthetase and reduces
cholesterol production without affecting the production of
the isoprenoids [27]. However, because squalestatin does
not cross the blood-brain barrier, it does not have clinical
application. Similar results were obtained in neurons
treated with simvastatin, a cholesterol synthesis inhibitor
that crosses the blood-brain barrier (data not shown). Sim-
vastatin is widely used clinically and has been reported to
reduce cholesterol levels within the brain [59,60].
Since cholesterol synthesis inhibitors affect many
cholesterol-sensitive processes, we sought to find a com-
pound with a more selective effect on rafts containing
Aβ. Here, we showed that inhibitors of cPLA2, an en-
zyme that is implicated in tubule formation and intracel-
lular trafficking [41-44], also affected Aβ42 distribution.
The activation of cPLA2 is the first step in the produc-
tion of PAF [61,62]. PAF is produced in neurons incu-
bated with Aβ42, and the amounts of PAF were elevated
in both the temporal cortex of patients with AD and in
murine AD models [63]. Our study suggested that the
effects of cPLA2 inhibitors on Aβ42 distribution were
mediated by a reduction in PAF production; not only did
PAF antagonists have similar effects as cPLA2 inhibitors,
but PAF also reversed the effects of cPLA2 inhibitors on
Aβ42 distribution and degradation.
Treating neurons with PLA2 inhibitors, PAF antago-
nists, or PAF did not affect total cellular cholesterol con-
centrations, suggesting that these drugs did not affect
cholesterol synthesis. PAF receptors were concentrated
in the ER, and PAF increased cholesterol concentrations
within ER fractions. Our studies are consistent with the
hypothesis that local cholesterol concentrations withinthe ER affect the formation and functional rafts involved
in the trafficking of Aβ42. Consequently, PAF antagonists
had similar effects to squalestatin on the trafficking of
Aβ42 in that they reduced the amount of Aβ42 within
rafts. PAF is involved in endocytosis and endosome for-
mation [64,65], and the blockade of PAF receptors may
block the formation of endocytic structures involved in
the trafficking or Aβ42. In neurons pre-treated with PAF
receptor antagonists, more Aβ42 was detected within ly-
sosomes, sites of protein degradation [66], and the half-
life of Aβ42 was reduced to less than 24 hours.
Notably, the PAF-induced increase in cholesterol was
accompanied by reduced cholesterol esters, suggesting
that cholesterol was being released from stores of chol-
esterol esters. The enzymes involved in the cholesterol
ester cycle, ACAT and CEH, were also concentrated in
the ER [67], and the PAF-induced increase in cholesterol
was blocked by inhibition of CEH. The role of CEH in
Aβ42 metabolism was demonstrated by using an inhibi-
tor of CEH [48], which greatly increased the degradation
of Aβ42 in a similar manner as PAF antagonists or squa-
lestatin. Collectively these results indicate that PAF regu-
lates the deacylation of cholesterol esters in the ER,
freeing cholesterol that affects the formation and function
of rafts which are involved in the trafficking of Aβ42.
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In summary, these results support the hypothesis that
Aβ42-induced activation of PLA2 leads to the production
of PAF which releases cholesterol from cholesterol es-
ters. The cholesterol helps stabilize Aβ42 in rafts which
traffic via a recycling pathway that avoids the lysosomes.
Thus, PAF receptor antagonists that reduce the release
of cholesterol affect the rafts that direct Aβ42 into the re-
cycling pathway as summarized in Figure 7. Conse-
quently, in these neurons, the half-life of Aβ42 was
greatly reduced. In neurons treated with cholesterol syn-
thesis inhibitors, PAF antagonists, or CEH inhibitors, the
trafficking of Aβ42 is altered so that Aβ42 was found out-
side rafts, was targeted to lysosomes, and rapidly de-
graded. The novel observation that the activation of
specific signaling pathways controls the trafficking and
degradation of Aβ42 may aid the development of drugs
to delay the progression of AD.
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